FY2024 Earnings Forecast for ONCY Issued By Raymond James

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Research analysts at Raymond James dropped their FY2024 earnings estimates for shares of Oncolytics Biotech in a research note issued to investors on Tuesday, November 12th. Raymond James analyst R. Sarugaser now forecasts that the company will earn ($0.32) per share for the year, down from their previous estimate of ($0.28). Raymond James has a “Moderate Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

A number of other research firms also recently issued reports on ONCY. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Price Performance

ONCY stock opened at $0.98 on Friday. The company has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.75. The firm’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.06.

Hedge Funds Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.